Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
about
Inflammatory bowel diseaseBacille Calmette-Guerin (BCG) vaccine for induction of remission in Crohn's diseaseMethotrexate for induction of remission in refractory Crohn's diseaseCorticosteroids for maintenance of remission in Crohn's diseaseOptimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel diseaseProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseRac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine TherapyThiopurines and inflammatory bowel disease: Current evidence and a historical perspectivePharmacogenetics in inflammatory bowel disease6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Conventional therapy for Crohn's diseaseMonitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel diseaseManagement of active Crohn disease.Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose.European evidence based consensus on the diagnosis and management of Crohn's disease: current management.Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanineImmunomodulators and immunosuppressants for Japanese patients with ulcerative colitisManagement of inflammatory bowel disease.Guidelines for the management of inflammatory bowel disease in adults.Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel diseaseProspective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study.Treatment of inflammatory bowel disease: a review of medical therapy.Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease.Immunomodulators for all patients with inflammatory bowel disease?Monitoring and safety of azathioprine therapy in inflammatory bowel disease.Low dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital.Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease.Thiopurine S-Methyltransferase Polymorphisms in Korean Dermatologic Patients.Practical guidelines for the treatment of inflammatory bowel disease.Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.Drug-induced eosinophilic pneumonia in a patient with Crohn's disease: diagnosis and treatment using fraction of exhaled nitric oxide.Mitigation of colitis with NovaSil clay therapy.NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients.
P2860
Q22242222-C7A3845E-3937-4904-84F1-553817F2A90FQ24241604-65F653B2-FB47-4B67-A728-5EDFDD5AABC1Q24245655-9AA59473-5677-4EEA-A1A8-583D9DB89903Q24247756-FD1FDB93-9094-454C-BF07-3FB441C2667EQ24631869-EC2397FC-9850-4C1F-992C-D321536FBE35Q26825174-20F0978C-28F2-47CC-B9BB-31608947D758Q26829392-0371F127-2A20-4EF4-9690-043473CBDF8CQ26866940-B8B07591-5361-43E0-B632-069C043C09C1Q28067937-B9CD3470-C9B6-45A5-B5FE-A35A7C9218ADQ28079644-80F07A87-2CCD-44D7-91D7-CD57008275DBQ28246002-4EBE3D73-8C83-4A8B-92D1-89BF1EEAAE51Q33436894-AC47A061-2271-4547-B421-15CF52837D16Q33654733-A1950662-323A-4C5A-845F-7D3FF0F963ABQ33866982-821C521F-8C8B-42D6-8469-EC606AACA76FQ33941619-8EE2A0FE-1163-499B-B870-7DA510B23E48Q34345967-D45AAE3E-F95F-4423-AC99-C67FEE619A98Q34549324-3F781A4D-14ED-4F3E-B15D-9E769BF647A1Q34564902-A943B665-72CC-486B-8D5E-51E24A937C71Q35036160-A1726439-B7F8-4F71-AB2D-31550AF451FFQ35200481-9CA8D731-F49C-44FF-910A-23B16873F182Q35519195-9D2AEE63-D0A5-4BB4-A8AB-F570B3EBC3A8Q35790559-63F529B8-D381-4FD8-A59E-06421390829AQ36230695-44C6C28C-D413-4752-89CD-B3E77AD67120Q36443655-093287F3-A8D0-4AE0-8041-F460B67E671CQ36822402-DE1E9385-2D45-484E-BD7B-EAEB4B4BDEEFQ37058862-3B83037C-6903-49E9-B51A-9AFF46B4ABF7Q37146097-2B76A3E0-36D3-4606-BE55-CF0EA0B3E17BQ37223169-AFBB621F-9939-4AFF-86B5-E919454BEB72Q37276962-B615C9B6-F156-452B-9578-0D90BBC9542CQ37823320-1BAE407B-FEEA-4EBC-9530-30E2E5843949Q38134756-1C95EA72-9C93-4821-9375-4B47605415C1Q38608975-DE612C35-9AC9-4C48-951D-D178D4977814Q41985008-D87B3007-9BB7-46D4-A434-AC527518467CQ42087184-5FE43F99-1914-42DE-82D6-390F2888CA8FQ42846582-BBB7048A-7CB9-47F9-BD26-4FD398C6D447Q42877648-B59DA2F7-A1B7-491E-B705-7BA4CA8451D6Q46194931-EDE544A2-D681-4303-B77F-4EAC9A38E854Q46836150-3025F7FC-B16F-4DB2-89D8-46685F56D256Q54975027-75F3C479-79B7-4E8C-BD81-D3B90E6539AD
P2860
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
description
2000 nî lūn-bûn
@nan
2000 թուականին հրատարակուած գիտական յօդուած
@hyw
2000 թվականին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@ast
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@en
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@nl
type
label
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@ast
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@en
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@nl
prefLabel
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@ast
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@en
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@nl
P2093
P2860
P3181
P1476
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
@en
P2093
P2860
P304
P3181
P356
10.1002/14651858.CD000545
P407
P577
2000-01-01T00:00:00Z